Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.51 |
| ▸ | TACR1 | P25103 | 5/20 | 0.49 |
| ▸ | NMBR | P28336 | 2/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306358 | 0.90 | CCKBR (0.51) | CCKBRTACR1NMBRTACR3KDM4E | |
| SCHEMBL22835926 | 0.84 | NMBR (0.53) | CCKBRTACR1NMBRTACR3KDM4E | |
| SCHEMBL6339800 | 0.83 | MAPT (0.52) | CCKBRTACR1NMBRTACR3KDM4E | |
| SCHEMBL3020294 | 0.83 | CTSL (0.59) | CCKBRTACR1TACR3MAPTSMN1; SMN2 | |
| SCHEMBL3020291 | 0.83 | CTSL (0.59) | CCKBRTACR1TACR3MAPTSMN1; SMN2 | |
| SCHEMBL9016089 | 0.83 | CTSL (0.59) | CCKBRTACR1TACR3MAPTSMN1; SMN2 | |
| SCHEMBL15145403 | 0.82 | NMBR (0.49) | CCKBRTACR1NMBRTACR3KDM4E | |
| SCHEMBL27572661 | 0.81 | CCKBR (0.52) | CCKBRTACR1NMBRTACR3KDM4E | |
| SCHEMBL23085871 | 0.81 | CCKBR (0.48) | CCKBRTACR1NMBRKDM4EMAPT | |
| SCHEMBL8901324 | 0.81 | NMBR (0.55) | CCKBRNMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906058-B2 | 1,5-Benzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | claimed |
| EP-1263747-B1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | claimed |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | ALBIREO AB (SE) | 2003-09-04 | — | — | US | claimed |
| EP-1263747-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | claimed |
| WO-2001066533-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | claimed |
| US-6906058-B2 | 1,5-Benzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| EP-1263747-B1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | ALBIREO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1263747-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066533-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | SLC10A2, SLC10A1, LCAT | CCKBR 418/4885TACR1 812/4885NMBR 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.